COVID-19 Rapid Diagnostic Test Market, by Product Type (Instruments and Reagents and Kits), by Sample Type (Nasopharyngeal Swabs, Oropharyngeal Swabs, Nasal Swabs, and Blood), by Test Type (Molecular testing, Antigen based testing, Antibody testing, and O

COVID-19 Rapid Diagnostic Test Market, by Product Type (Instruments and Reagents and Kits), by Sample Type (Nasopharyngeal Swabs, Oropharyngeal Swabs, Nasal Swabs, and Blood), by Test Type (Molecular testing, Antigen based testing, Antibody testing, and Others including CRISPR and Biosensors), by End Users (Hospitals and Clinics, Laboratories, and Diagnostic Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

A rapid diagnostic test of a sample of a person helps to detect the presence of viral proteins (antigens) related to the COVID-19 virus. This ensures an accurate and a speedy diagnosis, and its usage is Centers for Disease Control and Prevention CDC-approved. This test is a rapid diagnostic test based on antigen detection. The other test is rapid diagnostic test based on antibody detection. This test is used to detect the presence of antibodies in the blood of COVID-19 infected people. The strength of the antibody response depends on several factors like medications, age, infections, and the severity of disease, etc.
Molecular and antigen tests are types of diagnostic tests that can detect the infection if you have an active COVID-19 infection. Samples for diagnostic tests are normally collected with a throat or nasal swab, or saliva collected by spitting into a tube. Antibody tests look for antibodies in your immune system produced in response to SARS-CoV-2, the virus that is responsible for causing COVID-19. Antibody tests cannot be used to diagnose an active COVID-19 infection. Antibodies can take several days or weeks to develop after you get infected by the infection and may stay in your blood for several weeks or even after recovery from the infection. Samples for antibody tests are typically blood drawn by your doctor or other medical personnel.
Market Dynamics
The increasing number of approvals for new and advanced COVID-19 rapid diagnostic test kits by regulatory authorities is expected to propel the market growth over the forecast period. For instance, on May 12, 2021, Fujirebio Europe received CE mark for the molecular IVD assay iAMP COVID-19 detection kit, developed in partnership with Atila Biosystems, Inc., a U.S.-based company focused on developing products for nucleic acid amplification and detection of clinical diagnostic applications. Moreover, in September 2021, the U.S. FDA granted emergency use status to MiraDx, a U.S.-based molecular genetics company, for its SARS-CoV-2 RT-PCR assay used for detection of COVID-19.

Furthermore, development of cheaper COVID-19 detection kits is expected to drive the global COVID-19 rapid diagnostic test market growth over the forecast period. For instance, in January 2021, the World Health Organization approved a rapid antigen test developed by UNICEF (United Nations International Children’s Emergency Fund) for diagnosis of COVID-19 under emergency use. This COVID-19 diagnostic test is a low cost alternative to other more expensive COVID-19 test and is priced at US$ 2.55 per test. With the development of such low cost COVID-19 rapid diagnostic tests, low and middle income countries such as Bangladesh, Indonesia, and others would have more access to the COVID-19 diagnostic tests.
Key features of the study:
This report provides in-depth analysis of the global COVID-19 rapid diagnostic test market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global COVID-19 rapid diagnostic test market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Abbott Laboratories, F. Hoffmann-La Roche AG, Cardinal Health, Inc., Alfa Scientific Designs, Inc., Acon Laboratories, Inc., Thermo Fisher Scientific Inc., Danaher Corporation, PerkinElmer, Inc., Bio-Rad Laboratories, Inc., and Creative Diagnostics
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global COVID-19 rapid diagnostic test market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global COVID-19 rapid diagnostic test market
Detailed Segmentation:
Global COVID-19 Rapid Diagnostic Test Market, By Product Type:
Instruments
Reagents & Kits
Global COVID-19 Rapid Diagnostic Test Market, By Sample Type:
Nasopharyngeal (NP) Swabs
Oropharyngeal (OP) Swabs
Nasal Swabs
Blood
Others (others include Saliva)
Global COVID-19 Rapid Diagnostic Test Market, By Test Type:
Molecular Testing
Antigen-based Testing
Antibody Testing
Others (others include CRISPR and Biosensors)
Global COVID-19 Rapid Diagnostic Test Market, By End User:
Hospitals & Clinic
Laboratories & Diagnostics Centers
Others
Global COVID-19 Rapid Diagnostic Test Market, By Region:
North America
By Product Type
Instruments
Reagents and Kits
By Sample Type
Nasopharyngeal (NP) Swabs
Oropharyngeal (OP) Swabs
Nasal Swabs
Blood
Others (others include Saliva)
By Test Type
Molecular Testing
Antigen-based Testing
Antibody Testing
Others (others include CRISPR and Biosensors)
By End User
Hospitals and Clinic
Laboratories & Diagnostics Centers
Others
By Country
U.S.
Canada
Latin America
By Product Type
Instruments
Reagents and Kits
By Sample Type
Nasopharyngeal (NP) Swabs
Oropharyngeal (OP) Swabs
Nasal Swabs
Blood
Others (others include Saliva)
By Test Type
Molecular Testing
Antigen-based Testing
Antibody Testing
Others (others include CRISPR and Biosensors)
By End User
Hospitals and Clinic
Laboratories & Diagnostics Centers
Others
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type
Instruments
Reagents and Kits
By Sample Type
Nasopharyngeal (NP) Swabs
Oropharyngeal (OP) Swabs
Nasal Swabs
Blood
Others (others include Saliva)
By Test Type
Molecular Testing
Antigen-based Testing
Antibody Testing
Others (others include CRISPR and Biosensors)
By End User
Hospitals and Clinic
Laboratories & Diagnostics Centers
Others
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Product Type
Instruments
Reagents and Kits
By Sample Type
Nasopharyngeal (NP) Swabs
Oropharyngeal (OP) Swabs
Nasal Swabs
Blood
Others (others include Saliva)
By Test Type
Molecular Testing
Antigen-based Testing
Antibody Testing
Others (others include CRISPR and Biosensors)
By End User
Hospitals and Clinic
Laboratories & Diagnostics Centers
Others
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product Type
Instruments
Reagents and Kits
By Sample Type
Nasopharyngeal (NP) Swabs
Oropharyngeal (OP) Swabs
Nasal Swabs
Blood
Others (others include Saliva)
By Test Type
Molecular Testing
Antigen-based Testing
Antibody Testing
Others (others include CRISPR and Biosensors)
By End User
Hospitals and Clinic
Laboratories & Diagnostics Centers
Others
By Country
GCC
Israel
Rest of Middle East
Africa
By Product Type
Instruments
Reagents and Kits
By Sample Type
Nasopharyngeal (NP) Swabs
Oropharyngeal (OP) Swabs
Nasal Swabs
Blood
Others (others include Saliva)
By Test Type
Molecular Testing
Antigen-based Testing
Antibody Testing
Others (others include CRISPR and Biosensors)
By End User
Hospitals and Clinic
Laboratories & Diagnostics Centers
Others
By Country/Region
South Africa
Central Africa
North Africa
By Company Profiles :
Abbott Laboratories*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
F. Hoffmann-La Roche AG
Cardinal Health, Inc
Alfa Scientific Designs, Inc
Acon Laboratories, Inc
Thermo Fisher Scientific Inc
Danaher Corporation
PerkinElmer, Inc
Bio-Rad Laboratories, Inc
Creative Diagnostics

“*” marked represents similar segmentation in other categories in the respective section.